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Introduction
Arteriovenous malformations are fast-flow vascular malformations characterized by connections between feeding arteries and draining veins, and although rare, are 20 times more common in the CNS, including the brain and spinal cord (Gomes and Bernatz, 1970; Milton et al., 2012) . Brain arteriovenous malformations (BAVMs) occur in 1.3 per 100 000 patient years and are equally distributed across populations, while the prevalence of spinal arteriovenous malformations (SAVMs) is 1/10th of BAVMs and account for $20-30% in all spinal vascular malformations (Cogen and Stein, 1983) . Germline mutations can be associated with hereditary syndromes hallmarked by arteriovenous malformations, such as mutations in the TGF-b/SMAD pathway (Gallione et al., 2004) in hereditary haemorrhagic telangectasia (HHT) or in the RAS p21 protein activator 1 (RASA1) in the capillary malformation-arteriovenous malformation syndrome (CM-AVM) (Eerola et al., 2003; Lapinski et al., 2018) . However, sporadic vascular malformations are much more common and seem to be associated with somatic and not germline mutations. These include sporadic arteriovenous malformations, cavernous malformations (Couto et al., 2017; Al-Olabi et al., 2018; Nikolaev et al., 2018) , vascular anomalies found in Sturge-Weber syndrome (Shirley et al., 2013; Nakashima et al., 2014) , lymphatic and venous malformations (Limaye et al., 2009 (Limaye et al., , 2015 Castel et al., 2016; Castillo et al., 2016) as well as vascular tumours such as haemangiomas. From these studies, the emerging picture is that most of these lesions are associated with mutations commonly found in cancer, mainly in the PI3K-AKT-mTOR in low vascular malformations including venous and lymphatic malformations (Karpathiou et al., 2017) and RAS-MAPK pathway in high flow lesions including BAVMs (Al-Olabi et al., 2018; Nikolaev et al., 2018) . Specifically, activating mutations in KRAS, such as p.G12V and p.G12D, which are major cancer drivers, are associated with BAVMs (Nikolaev et al., 2018) . However, only about 60% of BAVMs harboured KRAS mutations with a significant number of BAVMs remaining without detected mutations and no somatic mutations have been reported in SAVMs. Here, using ultradeep next generation sequencing (NGS) with a panel of 422 tumour genes, we investigated whether the vast majority or all BAVMs and SAVMs are associated with detectable tumour-related somatic mutations.
Materials and methods

Patient enrolment and sample preparation
Twenty-one BAVM patients and 10 SAVM patients who underwent surgical resection of the nidus at the Beijing Xuanwu Hospital in China were recruited to this study. The study was approved by the ethics committee of Beijing Xuanwu Hospital (NO.2016032) and written informed consents from all patients or their guardians was obtained before surgery. All of the arteriovenous malformation diagnoses were made with imaging and pathological examinations by the study team. Patients demonstrating sporadic unifocal BAVMs/SAVMs with defined nidus structure were included. Patients with family history of arteriovenous malformations or documented genetic vascular diseases were excluded.
After surgical resection, the nidus was dissected from the tissue and was cut into equal samples. Together with matched whole blood samples, one of the tissue samples was sent to the sequencing facility of Nanjing Geneseeq Biotechnology Inc. (Nanjing, China) for NGS and droplet digital polymerase chain reaction (ddPCR) analyses.
Sample processing and library preparation
Genomic DNA was extracted from tissue samples and matched whole blood samples using DNeasy Õ Blood and Tissue Kit (Qiagen) following the manufacturer's recommended protocols. For each sample, 1-2 mg genomic DNA was fragmented using the Covaris M220 sonication system (Covaris) to 300-350 bp. Fragmented DNA was processed through end-repairing, A-tailing, and adaptor ligation using KAPA Hyper Prep Kit (KAPA Biosystems, KK8504), followed by size selection and purification using Agencourt AMPure XP beads (Beckman Coulter) with an optimized manufacturer's protocol. Finally, libraries were amplified by PCR and purified using Agencourt AMPure XP beads. Sample quality control was performed using NanoDrop TM 2000 (Thermo Fisher Scientific) for A260/280 and A260/230 ratios, and Bioanalyzer 2100 with High Sensitivity DNA kit (Agilent Technologies, 5067-4627) for size distribution. Sample and library quantification was performed using Qubit 3.0 dsDNA HS Assays (Life Technology).
Target enrichment and NGS
For targeted sequencing, a customized biotinylated probe panel (Integrated DNA Technologies) covering the exonic regions of 422 solid tumour-related genes and the intronic regions of a selected subset of the genes was used for hybridization enrichment. Libraries with different sample indices were pooled together in desirable ratios for up to 2 mg of total library. 0 ) by KAPA HiFi HotStart ReadyMix (KAPA biosystems), followed by purification using Agencourt AMPure XP beads.
Target-enriched libraries were quantified by qPCR using KAPA Library Quantification Kit (KAPA Biosystems). Sequencing was carried out on HiSeq4000 NGS platforms (Illumina) according to the manufacturer's instructions, with paired-end 150 bp sequencing chemistry. Sequencing depth was anticipated to be 1000 Â and 100 Â for tissue sample and whole blood samples, respectively.
Sequencing data analysis
Sample demultiplexing was carried out using bcl2fastq v2.16.0.10 (Illumina). Adaptor nucleotides and low quality base cells were removed by Trimmomatics (Bolger et al., 2014) . Paired-end sequencing reads were aligned to the human reference genome hg19 (Genome Reference Consortium Human Reference 37, GRCh37) using Burrows-Wheeler Aligner v0.7.12 (BWA-MEM) (Li and Durbin, 2009) . Samtools v1.6 was used to sort and index the aligned bam file . The bam file was further processed for PCR-duplicate removal by Picard v1.119 (https://broadinstitute.github.io/picard/) and for base recalibration and indel realignment by the Genome Analysis Toolkit v3.6 (GATK) (McKenna et al., 2010) .
MuTect somatic mode with default parameters was used for single nucleotide variant (SNV) identification (Cibulskis et al., 2013) . SNV displaying 41% population frequency within the 1000 Genomes project and dbSNP were also excluded (Sherry et al., 2001; Genomes Project et al., 2015) . Small insertions and deletions (indels) were detected using Scalpel (Fang et al., 2016) . Identified SNVs and indels were annotated with ANNOVAR (Wang et al., 2010) , and manually reviewed on Integrative Genomics Viewer (IGV).
Droplet digital polymerase chain reaction
To validate the NGS results, and to screen additional low variant frequency mutations that were below the detection limit of NGS method, ddPCR was carried out on all of our samples.
Detection of rare variants in KRAS (NM_004985.3) and BRAF (NM_004333.4) was performed on the QX200 ddPCR system (Bio-Rad). Primers and probes for KRAS c.191_196 dupACAGTG p.Ser65_Ala66insAspSer were customized and synthesized at Integrated DNA Technologies (IDT) with the following sequences: forward primer 5 0 -TGGAGAAACCTGTCT CTTGGA-3 0 , reverse primer 5 0 -CCCTCCCCAGTCCTCATG TA-3 0 , reference allele locked nucleic acid (LNA) probe 5 0 -FAM-TCTCGACACAGCA-3 0 , insertion allele specific LNA probe 5 0 -HEX-ACAGTGACAGTGCA-3 0 . Each reaction was set up containing 50 ng genomic DNA, 9 pmol of each primer, 5 pmol of each probe, and 10 ml of 2Â ddPCR Supermix for probes (No dUTP) (Bio-Rad) in a 20 ml reaction volume. The following PCR conditions were used: (i) an initial activation step at 95 C for 10 min; (ii) followed by 45 cycles of denaturation at 94 C for 30 s and annealing/elongation at 60 C for 1 min; (iii) followed by a final elongation at 60 C for 5 min. PCR temperature ramp rate was set at 2 C/s for every step. Primers and probes for KRAS c.35G4A p.Gly12Asp (dHsa MDV2510596), KRAS c.35G4T p.Gly12Val (dHsaMDV251 0592), KRAS c.35G4C p.Gly12Ala (dHsaMDV2510586), KRAS c.183A4T p.Gln61His (dHsaMDV2010131), KRAS c.181C4A p.Gln61Lys (dHsaMDV2511862), KRAS c.34G4T p.Gly12Cys (dHsaMDV2510584), and BRAF c.1799T4A p.Val600Glu (dHsaCP2000027 and dHsaCP2000028) were purchased from Bio-Rad. Each reaction was set up following the manufacturer's instructions and containing 50 ng genomic DNA. PCR was carried out following the manufacturer's instructions for each commercial assay. PCR products were then subjected to analysis by the QX-200 droplet reader and QuantaSoft TM Analysis Software (Bio-Rad). A sample is considered positive if it displays at least three positive droplets, and if the number of positive droplets is at least three times the average number of positive droplets observed in five replicates of NA18535 negative control. The concentrations of target alleles were calculated using QuantaSoft TM version 1.7.4 (BioRad) based on Poisson distribution.
Statistical analysis
Student's t-test and Pearson correlation were used to assess the difference and correlation between two groups of quantitative variables. A two-tailed probability value of 0.05 or less was considered statistically significant. Additional information can be found in the Supplementary material.
Data availability
The authors are willing to provide the raw data related to this manuscript upon request.
Results
Clinicopathological characteristics of patients
This cohort consisted of 22 males (71.0%) and nine (29.0%) females with a mean age of 28.6 AE 14.0 years (range 5-54 years). All patients had fresh nidus samples and matched blood samples. Twenty cases (64.5%) had ruptured BAVMs or SAVMs. Of the 21 patients with BAVMs, five had a Spetzler-Martin (SM) grade I, six a SM grade II, nine a SM grade III and one a SM grade IV lesion. Of the 10 patients with SAVMs, four had a type II (glomus) and six a type III (juvenile) SAVM (Table 1 and Fig. 1 ). 
Identification of somatic genetic variants by exome sequencing
Our panel included 422 tumour-related genes, the details of which can be found in Supplementary Typical dark flow void signal on the MRI T 2 -weighted images (left) indicate the niduses (white arrowhead) of arteriovenous malformation, which are surrounded by feeding arteries and draining veins. Feeding arteries (white arrow), nidus (white arrowhead), draining veins (black arrow) and high risk structure (white hollow arrowhead) can be identified clearly on the DSA (middle). Intraoperative images (right) demonstrate the tortuous dilated vessels on the surface of brain/spinal cord, of which the feeding arteries, nidus (white arrowhead), high risk structure (white hollow arrowhead), and the draining veins (black arrow) can be recognized easily.
mutations were found at codon 12: c.35G4A p.Gly12Asp, c.35G4T p.Gly12Val, c.34G4T p.Gly12Cys, and c.35G4C p.Gly12Asp mutations; at codon 61 c.183A4T p.Gln61His mutation; and at codon 66 c.191_196dupACAGTG p.S65_Ala66insAspSer mutation. Activating mutation in BRAF (NM_004333.4) c.1799T4A p.Val600Glu was also observed in one SAVM patient and one BAVM patient. For simplicity, we use p.G12D, p.G12V, p.G12C, p.G12A, p.Q61H, p.S65_A66insDS, and p.V600E in this manuscript when referring to these mutations, respectively. Representative NGS results of these mutations were shown in Fig. 2 . None of the seven mutations were annotated in the 1000 Genomes database. KRAS p.G12V, p.G12A and p.Q61H were not annotated in the ExAC Browser databases. KRAS p.G12D, p.G12C and BRAF p.V600E had ExAC allele counts of 2/101 204, 2/101 218 and 2/121 220, respectively. The other two mutations KRAS p.G12A, and p.S65_A66insDS have never previously been reported in SAVM and BAVM.
Confirmation of NGS mutations and identification of additional low variant frequency mutations with droplet digital PCR
The 21 KRAS and two BRAF mutations detected by panel sequencing of 422 panel genes were confirmed with ddPCR. Representative ddPCR results of these mutations are shown in Fig. 2 . As shown in Table 2 , four additional KRAS mutations were detected in eight exome sequencingnegative samples. The total prevalence of KRAS/BRAF mutations was therefore 87.1% (27 of 31) in our cohort. The variant frequencies of mutations verified by ddPCR ranged from 0.03% to 7.29%. The variant frequencies of the mutations determined by ddPCR showed strong correlation with the variant frequencies determined by NGS-based methods (r = 0.950, P 5 0.001) (Supplementary Fig. 1 ). (Fig. 3) .
Mutation variant frequencies are negatively correlated with nidus volumes and largest diameters, but not patient ages
Because of significant differences on nidus volume between SAVMs and BAVMs, we separately analysed their correlation with mutation variant frequencies in 10 patients with SAVM. The mutation variant frequency was negatively correlated with nidus volumes and largest diameters (r = À0.686, P = 0.028 in nidus volumes, and r = À0.764, P = 0.010 in nidus largest diameters, respectively). Similarly, in 20 patients with BAVM (nidus volume and largest diameter were not available in Patient 25 due to emergency surgery), the mutation variant frequencies were also negatively correlated with the two indices (r = À0.522, P = 0.038 in nidus volumes, and r = À0.524, P = 0.037 in nidus largest diameters, respectively). Furthermore, no significant correlation was found between mutation variant frequencies and ages (r = À0.338, P = 0.085) (Fig. 4) . Furthermore, patients were divided into two groups with the same number of patients according to variant frequencies. Significant differences on nidus length and volume were observed between the two subgroups with low and high variant frequencies. As shown in Table 3 , patients with low variant frequencies showed significantly larger lengths and volumes both in SAVM and in BAVM. In these analyses, we used ddPCR variant frequencies as the mutation variant frequencies.
Discussion
In this study, we profiled 31 CNS arteriovenous malformations, including BAVMs and SAVMs, for somatic mutations in a panel of 422 tumour-related genes. The key findings of our study are (i) high prevalence (nearly 90%) of KRAS/BRAF somatic mutations in BAVMs and SAVMs with no other tumour gene mutations replicated using ultradeep panel sequencing; (ii) the first evidence of activating BRAF mutations in BAVMs and SAVMs; and (iii) evidence that SAVMs, a disease previously uncharacterized at the genetic level, share the same highly prevalent mutations in KRAS and BRAF with BAVMs. Moreover, we also observed two novel mutations in KRAS (p.G12A and p.S65_A66insDS) in CNS arteriovenous malformations. Finally, we found that mutation variant frequencies negatively correlated with nidus volumes and largest diameters Each dot represents a droplet. Blue: the droplet encloses at least one copy of mutant template. Green: the droplet encloses at least one copy of wildtype template. Orange: the droplet encloses at least one copy of wild-type and mutant template. Black: the droplet encloses no target molecular.
but not with age, a finding that may have implications for the understanding of the pathogenesis of arteriovenous malformations.
High prevalence of somatic KRAS/BRAF mutation
Recently, activating somatic KRAS mutations were observed with a relatively high prevalence of 64% in BAVMs, and associated with the activation of the MAPK/ ERK pathway, one of the major intracellular signalling pathway downstream of KRAS (Nikolaev et al., 2018) . Consistently, activated mosaic mutations in four MAPK pathway genes, i.e. KRAS, NRAS, BRAF and MAP2K1 were described in intracranial and extracranial vascular malformations including high flow arteriovenous malformations (Couto et al., 2017; Al-Olabi et al., 2018) , reinforcing the role of the RAS/RAF/MAPK/ERK pathway in arteriovenous malformations. Interestingly, BAVMs without detectable KRAS mutations also had high levels of phorphorylated ERK1/2, suggesting that the RAS/RAF/ MAPK/ERK pathway activation is a hallmark of all BAVMs (Nikolaev et al., 2018) . Intriguingly, KRAS mutations as well as its downstream effector BRAF mutations also occurred at high frequency in endoderm-derived tumours and played a role in their progression, through the RAS-RAF-MEK-MAPK pathway or the PI3K-AKT-PTENmTOR pathway (shared the same upstreaming tyrosine kinase with RAS-RAF-MEK-MAPK) (Quinlan et al., 2008; Millington, 2013; Simanshu et al., 2017) . Our study not only confirms the presence of activating KRAS mutations in BAVMs, but also finds a much higher prevalence of 87.1% of KRAS/BRAF mutation in BAVMs/ SAVMs than previously reported values (Al-Olabi et al., 2018; Nikolaev et al., 2018) . This difference is most likely accredited to the ultradeep sequencing (1077Â) of a restricted panel of genes used in our study compared to the lower depth whole exome sequencing used by Nikolaev et al. (2018) and possibly differences in tissue preparation, ddPCR methodology and calling thresholds. Importantly, our study provides the first evidence of BRAF mutations in CNS arteriovenous malformations both in the brain and spinal cord. Knowing that a BRAF mutation has previously been found in only one arteriovenous malformation sample from an extracranial skin arteriovenous malformation (AlOlabi et al., 2018), which is again consistent with the centrality of the RAS/RAF/MAPK pathway in arteriovenous malformations.
The fact that all of the mutations found in arteriovenous malformations, including KRAS p.G12V and p.G12D, and BRAF p.V600E and MAP2K1, result in oncogenic activation of these genes and are all drivers of cancer growth in humans (Cichowski and Janne, 2010; Prior et al., 2012; Simanshu et al., 2017) contrasts with their presence in the majority of arteriovenous malformations, which are not tumoural vascular growths. This points to a tissue-specific and context-dependent role of the RAS/RAF/MAPK pathway in vascular tissue or perhaps a need for multiple additional genetic hits to sustain cancer as opposed to a monogenetic nature of arteriovenous malformations. This (Long et al., 2014) . Knowing that nearly all BAVMs and SAVMs have mutations in either KRAS or BRAF, permits the opportunity of initiating therapy in potential clinical trials without previous tissue sampling and genetic confirmation, which is not feasible in BAVMs or SAVMs outside of total resection.
Genetic homogeneity in SAVMs and BAVMs
BAVMs and SAVMs belong to CNS vascular malformations and may therefore share a similar pathogenesis, differing only by their different location along the neuraxis. Concomitant BAVM and SAVM patients have been reported in literature, which may be the evidence of the embryological homology (Hasegawa et al., 1999; Wang et al., 2009; Shallwani et al., 2012) . It may occur at a different site of neuraxis between the fourth and eighth weeks of embryonic development, then disperse and form the nidus in a different part of the CNS. Both, in addition to sharing angioarchitectural features of high flow arteriovenous malformations, are characterized by aberrant angiogenesis and vascular remodelling (Aminoff and Logue, 1974; Kim and Spetzler, 2006; Kawamoto and Losordo, 2008; RangelCastilla et al., 2014) . In our previous study, we demonstrated that both BAVMs and SAVMs share similar immunohistochemistry features (Gao et al., 2010 (Gao et al., , 2011 . Besides, endothelial cells, as well as the endothelial progenitor cells, mediate pathological vascular remodelling and impact the clinical course of both BAVM and SAVM. However, the genetic basis of SAVMs remains unexplored. Here, we elucidate the genetic basis of a majority of SAVMs, albeit in a small cohort of 10 patients, and show that they harbour the same somatic mutations in BRAF and KRAS with comparable prevalences as BAVMs. Our findings, together with previous studies on brain and extracranial arteriovenous malformations (Couto et al., 2017; Al-Olabi et al., 2018; Nikolaev et al., 2018) , may suggest a relative genetic homogeneity of all high flow arteriovenous malformations, within which mutations occur in different genes of the same signalling pathway.
KRAS/BRAF mutation variant frequency and arteriovenous malformation size
The finding of recurrent highly prevalent KRAS/BRAF mutations in both BAVMs and SAVMs, the pathogenic nature of those mutations, the absence of KRAS/BRAF mutations in brain vascular malformations other than BAVMs (Nikolaev et al., 2018) , and the direct induction of arteriovenous malformation-like lesions by a mutation in an animal model (Al-Olabi et al., 2018) , convergently support that KRAS/BRAF mutations are causative and not bystander events due to endothelial proliferation, angiogenic signalling or vascular remodelling in arteriovenous malformations. Moreover, the absence of correlation of mutation variant frequencies with patient age and the negative correlation with arteriovenous malformation size in our study, is inconsistent with a passenger mutation hypothesis where KRAS/BRAF mutations would randomly accumulate with time and lesion growth. On the contrary, a negative correlation between variant frequencies and arteriovenous malformation size may support the view that arteriovenous malformations result from the clonal progeny of an endothelial precursor acquiring a somatic mutation and initiating the pathogenesis of the arteriovenous malformations. In this scenario, with tissue growth and endothelial turnover, wild-type endothelial cells would also be incorporated in the arteriovenous malformation, therefore diluting the mutant arteriovenous malformation cells. However, the high cell heterogeneity of arteriovenous malformation tissue may be an alternative explanation of our findings. For example, a potentially different cell ratio between endothelial and mural cells in small and large arteriovenous malformations may also result in a dilution of mutation variant frequencies in large lesions. Further analysis of endothelial cells isolated from BAVMs and SAVMs would resolve this question. Recently, EPHB4 mutations were identified in vein of Galen aneurysmal malformation (Vivanti et al., 2018) , and somatic inactivating RASA1 mutation was identified in capillary malformation lesion tissue in a patient with germline RASA1 mutation (Lapinski et al., 2018) . Those genes involved in vascular malformation in previous studies could be potential somatic mutated genes in arteriovenous malformation tissues, such as RASA1, EPHB4, ENG, ACVRL1, GDF2, NF1 etc. (Matsubara et al., 2000; Eerola et al., 2003; Mahmoud et al., 2010; Chida et al., 2013; Tualchalot et al., 2014; Lapinski et al., 2018; Vivanti et al., 2018) . Before targeted ultradeep 422-gene exome sequencing, whole exome sequencing was also performed in 12 of our cohort and no somatic mutations were detected within these genes. Despite that, we advocated the idea of profiling the genes whose hotspot mutations have been previously associated with vascular malformation when practicing clinical management of vascular malformation. A targeted exome NGS panel designated for arteriovenous malformations including both tumour-related somatic mutation genes and vascular malformation mutation genes should be developed in the future.
Another related unresolved question is whether KRAS/ BRAF mutations are single and sufficient causative events in BAVMs and SAVMs or if another genetic event is required, either as a preceding germline or somatic mutation or an ulterior second hit. The injection of BRAF V600E into single-cell zebrafish embryos to generate post-zygotic expression, resulted in only 10-20% vascular malformation in a recent study (Al-Olabi et al., 2018) and these authors speculated that the first hit is one germline mutation and/or other somatic mutation, and the second hit is KRAS/BRAF mutation, which eventually causes arteriovenous malformations. According to our results, we speculate that the KRAS/BRAF mutation is more likely the first hit. Future studies are needed to elucidate these mechanisms.
Conclusion
Our findings support a causative role of somatic activating mutations in KRAS/BRAF in the overwhelming majority of BAVMs and SAVMs. Practically and importantly, this pathway homogeneity in CNS arteriovenous malformations also supports the development of targeted therapies with RAS/RAF/MAPK pathway inhibitors without the necessity of tissue genetic diagnosis, a major obstacle if mutations were distinct pathways involved in arteriovenous malformations.
